Loading…
Chemomab Therapeutics Ltd. is projected to rise to $2.06 by 2027, a +27% move from its current price of $1.62. CMMB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/4/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $1.55 | $1.62 | $1.70 | +0.15% |
| Aug 6 | $1.53 | $1.62 | $1.73 | +0.30% |
| Aug 7 | $1.51 | $1.63 | $1.76 | +0.45% |
| Aug 8 | $1.49 | $1.63 | $1.78 | +0.59% |
| Aug 9 | $1.48 | $1.63 | $1.80 | +0.74% |
| Aug 10 | $1.47 | $1.63 | $1.82 | +0.89% |
| Aug 11 | $1.46 | $1.64 | $1.84 | +1.04% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.46 | $1.64 | $1.84 | +1.04% |
| Week 2 | $1.40 | $1.65 | $1.95 | +2.10% |
| Week 3 | $1.37 | $1.67 | $2.04 | +3.16% |
| Week 4 | $1.34 | $1.69 | $2.13 | +4.23% |
| Week 5 | $1.32 | $1.71 | $2.21 | +5.32% |
| Week 6 | $1.30 | $1.72 | $2.29 | +6.42% |
| Week 7 | $1.28 | $1.74 | $2.37 | +7.53% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Chemomab Therapeutics Ltd. is a clinical-stage biotechnology company focused on discovery and development of therapeutics for the treatment of fibrotic and inflammatory diseases. Its lead product candidate is nebokitug, a humanized monoclonal antibody that attenuates the basic function of CCL24 as a regulator of major inflammatory and fibrotic pathways, which has completed phase 2 clinical trial for treating primary sclerosing cholangitis, as well as in phase 2 clinical trial to treat systemic sclerosis.
The company was founded in 2011 and is based in Tel Aviv-Yafo, Israel.
Chemomab Therapeutics Ltd. is currently priced at $1.53 per share, with a market capitalization of $11.21M and a global rank of 4779. The near-term price outlook is informed by a multi-year forecast that spans 2026 through 2050 and shows a wide range of possible outcomes.
Forecasts indicate 2026 avg prices around $1.53 with a neutral sentiment, and progressively higher averages in later years such as 2027 avg $1.94, 2032 avg $2.77, 2040 avg $4.25, and 2050 avg $8.78, with corresponding ROIs highlighted up to 474.1% by 2050. The forecast also notes substantial upside in later years while near-term risk remains.
Overall, the picture suggests potential long-run upside, capped by near-term volatility and a bearish near-term sentiment, with max projections reaching as high as $20.18 by 2050.
A major floor 70.2% below — a decisive break under it would weaken the trend.
The nearest floor, 16.0% below — buyers have tended to step in here.
The nearest ceiling, 71.0% above — a clean break opens room to run.
A major ceiling 103.9% above — clearing it would confirm fresh momentum.
Key CMMB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CMMB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.48 | Buy | $1.50 | Buy |
| MA 10 | $1.45 | Buy | $1.50 | Buy |
| MA 20 | $1.65 | Sell | $1.56 | Buy |
| MA 50 | $1.71 | Sell | $1.65 | Sell |
| MA 100 | $1.70 | Sell | $1.74 | Sell |
| MA 200 | $1.94 | Sell | $2.15 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 47.79 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | -27.76 | Neutral |
| Williams %R (14) | -5.00 | Info |
| MACD (12,26,9) | -0.00 | Sell |
| ROC (12) | 1.97 | Buy |
| Bollinger %B (20,2) | 0.43 | Neutral |
| Stochastic %K (14) | 95.00 | Sell |
| TRIX (15) | -0.63 | Sell |
| Awesome (5,34) | -0.16 | Sell |
| Ultimate (7,14,28) | 60.73 | Neutral |
| Momentum (10) | -0.01 | Sell |
| Aroon Osc (25) | -52.00 | Sell |
| Hull MA (9) | 1.52 | Buy |
| ADX (14) | 14.97 | Neutral |
| ATR (14) | 0.08 | Info |
Near-term technical picture is BEARISH. The RSI(14) sits at 50, indicating neutral momentum around the midpoint. The stock’s short-term moving averages show SMA50 at $1.71 and SMA200 at $1.95, outlining nearby trend guides.
Key support sits at $1.36 and resistance at $2.77, framing a relatively wide trading range. The 30-day range currently spans from $1.14 up to $2.06, highlighting notable near-term volatility.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $1.36 | $1.62 | $2.61 | 0% | Neutral | |
| $1.55 | $2.06 | $2.93 | +27% | Bullish | |
| $1.41 | $1.97 | $2.97 | +22% | Bullish | |
| $1.55 | $2.25 | $3.54 | +39% | Bullish | |
| $1.32 | $1.99 | $3.24 | +23% | Bullish | |
| $1.39 | $2.16 | $3.64 | +34% | Bullish | |
| $1.88 | $3.03 | $5.23 | +87% | Bullish | |
| $1.91 | $3.17 | $5.61 | +96% | Bullish | |
| $1.96 | $3.34 | $6.04 | +106% | Bullish | |
| $1.80 | $3.15 | $5.82 | +95% | Bullish | |
| $2.35 | $4.71 | $9.46 | +191% | Bullish | |
| $4.52 | $10.04 | $22.74 | +520% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $1.36 | $1.62 | $2.15 | +0.00% |
| September 2026 | $1.55 | $1.86 | $2.33 | +15.05% |
| October 2026 | $1.52 | $1.85 | $2.36 | -0.51% |
| November 2026 | $1.55 | $1.91 | $2.45 | +2.83% |
| December 2026 | $1.62 | $2.00 | $2.61 | +5.07% |
Click any year to see its month-by-month CMMB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect CMMB to range from $1.36 to $2.61 through 2026. The $1.62 average target implies a 0% move from current prices. Price action looks broadly range-bound.
The CMMB price prediction for 2027 points to an average of $2.06 (low $1.55, high $2.93) — a potential gain of +27% on today's $1.62. Buyers look set to stay in control over this stretch.
In 2028, CMMB is projected to trade between $1.41 and $2.97, averaging $1.97 — a potential gain of +22% from today's $1.62. That is -4% versus the projected 2027 average. Momentum favours further upside here.
Chemomab Therapeutics Ltd.'s 2029 outlook centres on $2.25, within a $1.55 to $3.54 range. That is up +14% on the projected 2028 average. That marks a +39% change versus current levels. Buyers look set to stay in control over this stretch.
By 2030, CMMB could reach as high as $3.24, with a base case around $1.99 and support toward $1.32 — roughly +23% from $1.62. Momentum favours further upside here.
Expect CMMB to range from $1.39 to $3.64 through 2031. The $2.16 average target implies a +34% move from current prices. That is up +9% on the projected 2030 average. Buyers look set to stay in control over this stretch.
The CMMB price prediction for 2032 points to an average of $3.03 (low $1.88, high $5.23) — a potential gain of +87% on today's $1.62. Momentum favours further upside here.
In 2033, CMMB is projected to trade between $1.91 and $5.61, averaging $3.17 — a potential gain of +96% from today's $1.62. That is up +5% on the projected 2032 average. Buyers look set to stay in control over this stretch.
Chemomab Therapeutics Ltd.'s 2034 outlook centres on $3.34, within a $1.96 to $6.04 range. That is up +5% on the projected 2033 average. That marks a +106% change versus current levels. Momentum favours further upside here.
By 2035, CMMB could reach as high as $5.82, with a base case around $3.15 and support toward $1.80 — roughly +95% from $1.62. Buyers look set to stay in control over this stretch.
Expect CMMB to range from $2.35 to $9.46 through 2040. The $4.71 average target implies a +191% move from current prices. That is up +49% on the projected 2035 average. Momentum favours further upside here.
The CMMB price prediction for 2050 points to an average of $10.04 (low $4.52, high $22.74) — a potential gain of +520% on today's $1.62. Buyers look set to stay in control over this stretch.
Investing $1,000 in CMMB today (≈ 617.283951 CMMB) could be worth
$6,200.18
+$5,200.18 (+520%) by 2050 · US Dollar
Based on the average projected CMMB price of $10.04 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CMMBwould be worth at today's price.
$1,000 invested in CMMB on Jul 31, 2025 (≈ 233.644848 CMMB) would be worth
$378.5
-$621.5 (-62.1%) today · 0.38× · US Dollar
Based on a CMMB entry price of $4.28 vs. today's $1.62.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.36 | $1,191.18 | +19.1% |
| 1 month ago | $1.7 | $952.94 | -4.7% |
| 3 months ago | $1.61 | $1,007.46 | +0.7% |
| 6 months ago | $1.67 | $970.06 | -3.0% |
| 1 year ago | $4.28 | $378.5 | -62.1% |
| All time (5.0y) ago | $65.64 | $24.68 | -97.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CMMB forecast.
Our base-case forecast reaches $3.20 around 2034.
Implied market cap at $3.20: $23.45M
The multi-year forecast points to a slow-to-moderate near-term start with a more pronounced upside in several later years. Notably, 2027 Avg $1.94 with ROI 27% and bullish sentiment start the bulish drift, followed by 2028 Avg $1.87 (ROI 21.9) and 2029 Avg $2.12 (ROI 38.3). By 2030, the Avg is $1.82 with ROI 18.8 and neutral sentiment, and then the path improves through 2032 Avg $2.77 (ROI 80.9), 2033 Avg $2.88 (ROI 88.5), 2034 Avg $3.05 (ROI 99.4), and 2035 Avg $2.86 (ROI 86.9) as bullish momentum grows.
The horizon strengthens further with 2040 Avg $4.25 (ROI 177.7) and 2050 Avg $8.78 (ROI 474.1), both carrying bullish sentiment. The forecast also shows a max across years up to $20.18 by 2050. These are estimates, not guarantees, and reflect varying levels of upside and risk driven by market dynamics and outcomes in clinical development as presented by the data.
Tap a question to reveal the answer.
2030 min $1.20, avg $1.82, max $2.99; ROI 18.8; sentiment NEUTRAL.
The forecast shows years with bullish momentum (e.g., 2027 avg $1.94; 2029 avg $2.12; 2040 avg $4.25; 2050 avg $8.78) and a max of $20.18 by 2050, but near-term sentiment is BEARISH and volatility is high (annualized volatility 90%), so outcomes are uncertain.
Yes. The forecast shows maxima above $5 in several years: 2033 max $5.15, 2034 max $5.58, 2035 max $5.34, with later years like 2040 max $8.64 and 2050 max $20.18.
Current price is $1.53 and market cap is $11.21M.
The near-term stance is BEARISH. RSI(14) is 50, with SMA50 at $1.71 and SMA200 at $1.95. Support is $1.36 and resistance is $2.77; the 30-day range is $1.14 to $2.06.
Chemomab Therapeutics Ltd. Community Discussion
0Share your Chemomab Therapeutics Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.